|
業務類別
|
Biotechnology |
|
業務概覽
|
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates inSwitzerland, Spain, the United States, and Australia. |
| 公司地址
| 4800 Montgomery Lane, Suite 220, Bethesda, MD, USA, 20814 |
| 電話號碼
| +1 301 500-1556 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.gaintherapeutics.com |
| 員工數量
| 25 |
| Mr. Gianluca Fuggetta |
Senior Vice President, Finance, Principal Financial Officer and Principal Accounting Officer |
美元 204.49K |
07/01/2025 |
| Mr. Gene Mack |
Director, Chief Executive Officer and President |
美元 270.62K |
07/01/2025 |
|
|
| Dr. Dov A. Goldstein, M.B.A.,M.D. |
Independent Director |
29/04/2025 |
| Mr. Hans Peter Hasler |
Independent Director |
29/04/2025 |
| Dr. Claude Nicaise,M.D. |
Independent Director |
29/04/2025 |
| Dr. Khalid Islam, PhD |
Executive Chairman of the Board |
29/04/2025 |
| Ms. Gwen A. Melincoff |
Independent Director |
29/04/2025 |
| Mr. Jeffrey Riley |
Independent Director |
29/04/2025 |
| Mr. Gene Mack |
Director, Chief Executive Officer and President |
07/01/2025 |
|
|
|
|
